EA201170300A1 - Кристаллические формы пиридинового производного - Google Patents
Кристаллические формы пиридинового производногоInfo
- Publication number
- EA201170300A1 EA201170300A1 EA201170300A EA201170300A EA201170300A1 EA 201170300 A1 EA201170300 A1 EA 201170300A1 EA 201170300 A EA201170300 A EA 201170300A EA 201170300 A EA201170300 A EA 201170300A EA 201170300 A1 EA201170300 A1 EA 201170300A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crystal forms
- pyridine derivative
- solvate
- therapy
- compound
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0814340.6A GB0814340D0 (en) | 2008-08-05 | 2008-08-05 | Anhydrous crystol form fo a pyridine derivative |
| PCT/EP2009/060089 WO2010015626A1 (en) | 2008-08-05 | 2009-08-04 | Crystalline forms of a pyridine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201170300A1 true EA201170300A1 (ru) | 2011-08-30 |
Family
ID=39767571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170300A EA201170300A1 (ru) | 2008-08-05 | 2009-08-04 | Кристаллические формы пиридинового производного |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8093242B2 (enExample) |
| EP (1) | EP2321324A1 (enExample) |
| JP (1) | JP2011529942A (enExample) |
| KR (1) | KR20110052686A (enExample) |
| CN (1) | CN102171219A (enExample) |
| AU (1) | AU2009279135B2 (enExample) |
| BR (1) | BRPI0917224A2 (enExample) |
| CA (1) | CA2733235A1 (enExample) |
| EA (1) | EA201170300A1 (enExample) |
| GB (1) | GB0814340D0 (enExample) |
| IL (1) | IL210777A0 (enExample) |
| MX (1) | MX2011001414A (enExample) |
| WO (1) | WO2010015626A1 (enExample) |
| ZA (1) | ZA201100426B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011023733A1 (en) * | 2009-08-27 | 2011-03-03 | Glaxosmithkline Llc | Anhydrate forms of a pyridine derivative |
| CA2984591A1 (en) * | 2015-05-18 | 2016-11-24 | Nerre Therapeutics Limited | Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases |
| SG11202008226YA (en) | 2018-03-14 | 2020-09-29 | Kandy Therapeutics Ltd | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists |
| JOP20220111A1 (ar) | 2019-11-15 | 2023-01-30 | Kandy Therapeutics Ltd | عملية كيميائية جديدة لتشكيل 6-كلورو-4- (4-فلورو-2-مثيل فنيل) بيريدين-3-أمين بصفته مركباً وسيطاً رئيسياً لـ nt-814 |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0912174B1 (en) | 1996-07-17 | 2004-04-28 | MERCK & CO., INC. | Alteration of circadian rhythmicity with non-peptidal neurikinin-1 receptor antagonists |
| DE60014216T2 (de) | 1999-02-24 | 2006-03-02 | F. Hoffmann-La Roche Ag | 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten |
| WO2001030348A1 (en) | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0203022D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| EP1643998B1 (en) * | 2003-07-03 | 2007-08-29 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
| JO2722B1 (en) * | 2005-09-09 | 2013-09-15 | سميث كلاين بيتشام كوربوريشن | New vehicles |
-
2008
- 2008-08-05 GB GBGB0814340.6A patent/GB0814340D0/en not_active Ceased
-
2009
- 2009-08-04 BR BRPI0917224A patent/BRPI0917224A2/pt not_active IP Right Cessation
- 2009-08-04 WO PCT/EP2009/060089 patent/WO2010015626A1/en not_active Ceased
- 2009-08-04 US US13/056,775 patent/US8093242B2/en active Active
- 2009-08-04 EA EA201170300A patent/EA201170300A1/ru unknown
- 2009-08-04 AU AU2009279135A patent/AU2009279135B2/en not_active Ceased
- 2009-08-04 MX MX2011001414A patent/MX2011001414A/es unknown
- 2009-08-04 JP JP2011521561A patent/JP2011529942A/ja not_active Withdrawn
- 2009-08-04 CA CA2733235A patent/CA2733235A1/en not_active Abandoned
- 2009-08-04 EP EP09781468A patent/EP2321324A1/en not_active Withdrawn
- 2009-08-04 CN CN2009801393221A patent/CN102171219A/zh active Pending
- 2009-08-04 KR KR1020117005159A patent/KR20110052686A/ko not_active Withdrawn
-
2011
- 2011-01-17 ZA ZA2011/00426A patent/ZA201100426B/en unknown
- 2011-01-20 IL IL210777A patent/IL210777A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010015626A1 (en) | 2010-02-11 |
| ZA201100426B (en) | 2012-03-28 |
| GB0814340D0 (en) | 2008-09-10 |
| JP2011529942A (ja) | 2011-12-15 |
| BRPI0917224A2 (pt) | 2015-11-24 |
| IL210777A0 (en) | 2011-03-31 |
| EP2321324A1 (en) | 2011-05-18 |
| AU2009279135A1 (en) | 2010-02-11 |
| KR20110052686A (ko) | 2011-05-18 |
| CN102171219A (zh) | 2011-08-31 |
| MX2011001414A (es) | 2011-04-04 |
| US8093242B2 (en) | 2012-01-10 |
| CA2733235A1 (en) | 2010-02-11 |
| AU2009279135B2 (en) | 2012-09-13 |
| US20110136798A1 (en) | 2011-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201100030A1 (ru) | Пиразольные соединения 436 | |
| EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
| BRPI0916735B8 (pt) | compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos | |
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| MY171577A (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| EA201270302A1 (ru) | Безводные формы производных пиридина | |
| EA201491824A1 (ru) | Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1 | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| EA201592055A1 (ru) | 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов | |
| EA201001769A1 (ru) | Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы | |
| EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
| EA201492005A1 (ru) | Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1 | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| BR112014018702A8 (pt) | Composto, cristal, inibidor, medicamento, composição farmacêutica, e, uso de um composto ou sal | |
| EA201490864A1 (ru) | Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов | |
| NO20090628L (no) | Pyridizinon derivativater | |
| EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
| EA201300200A1 (ru) | N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме | |
| BR112012033402A2 (pt) | moduladores de canais de íons conforme os compostos heterocíclicos fundidos | |
| EA201390381A1 (ru) | Триазиноксадиазолы | |
| EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
| EA201490569A1 (ru) | Полиморфная форма гидрохлорида придопидина | |
| EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение |